Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Sustained or differential release type

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

424464000 - Tablets, lozenges, or pills

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424472000 Layered unitary dosage forms 112
424469000 Discrete particles in supporting matrix 28
424471000 Plural concentric cores 9
Entries
DocumentTitleDate
20120201886Coated Extended Release Pharmaceutical Compositions Containing Paliperidone - A non-osmotic coated extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients and process for preparing the same. The present invention particularly relates to a non-osmotic coated extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients wherein the core is coated with a release controlling composition.08-09-2012
20090123540Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof - A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.05-14-2009
20090196923CONTROLLED RELEASE FORMULATION COMPRISING ANTI-EPILEPTIC DRUGS - The present invention relates to pharmaceutical formulation of antiepileptic drug preferably oxcarbazepine. The formulation comprises multiple tablets or pellets of immediate release or controlled release nature, which are filled, inside the capsule to provides drug effect for 24 hours and is suitable for once a day administration. The patent also provides process of preparation of the dosage form.08-06-2009
20080260824Bioadhesive Rate-Controlled Oral Dosage Formulations - The present invention relates to a bioadhesive drug delivery system (BIOadhesive Rate controlled Oral Dosage (BIOROD) formulation) in which a drug containing core either alone or coated with a rate controlling membrane system is enveloped on its circumference by a bioadhesive coating, thereby yielding a monolithic system that allows for drug release in a regulated manner. Also described herein are polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers.10-23-2008
20100129445GASTRORETENTIVE SYSTEM COMPRISING AN ALGINATE BODY - Gastroretentive systems which have at least one release device for at least one active pharmaceutical ingredient and at least one swelling body that is connected to the release device.05-27-2010
20110195122Extended Release Formulation - The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof.08-11-2011
20110195121 CHRONOTHERAPEUTIC PHARMACEUTICAL DOSAGE FORM - This invention relates to a pharmaceutical dosage form for the phase-controlled and chronotherapeutic delivery of at least one and, preferably, several pharmaceutically active ingredients. The dosage form has a carrier platform which,—preferably, is a polymer having known biodegradable characteristics. The platform may include a pharmaceutically active ingredient'which is released over a predetermined period of time as the platform polymer degrades. At least one pharmaceutically active ingredient in the form of a disc is embedded in the platform and, once the polymer of the platform has degraded, the disc is released and releases its ingredient in the same location as that of the platform or it travels to another region of the body where it releases its ingredient.08-11-2011
20090214643IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES - Methods for administering beta-adrenergic inverse agonists with improved pharmacokinetic profiles for the treatment of pulmonary airway diseases are disclosed. The beta adrenergic inverse agonists are formulated in a controlled-release formulation comprising: (1) a beta-adrenergic inverse agonist in a therapeutically effective quantity; and (2) at least one agent that controls release of the beta-adrenergic inverse agonist resulting in a pharmacokinetic profile that minimizes acute detrimental reduction in airway function with the first dose and with each successive dose. This pharmacokinetic profile typically results in slow release of the drug into the bloodstream resulting in a large average T08-27-2009
20120183611ORAL PHARMACEUTICAL COMPOSITION COMPRISING DICLOFENAC - The invention relates to a specific oral diclofenac formulation with beneficial both immediate-release and sustained-release properties.07-19-2012
20130034604EXTENDED RELEASE FORMULATIONS OF DESVENLAFAXINE BASE - An extended release pharmaceutical composition comprising micronized desvenlafaxine base, at least one pH modifier and at least one release controlling agent and its process for preparation. An extended release monolithic tablet is also provided. Further extended release tablets comprising micronized desvenlafaxine base; at least one pH modifier; at least one release controlling agent; and at least one binder; wherein, the proportion of binder in the tablet is greater than about 3.0% of the total weight of the tablet and wherein, the pH modifier is present in a proportion of more than about 15 parts for each of the 100 parts of the desvenlafaxine base is also provided. Also provided is process for preparation of extended release tablet.02-07-2013
20100104638EXTENDED RELEASE ORAL ACETAMINOPHEN/TRAMADOL DOSAGE FORM - An extended release oral administered dosage form of acetaminophen and tramadol. The dosage form includes a composition of acetaminophen together with a tramadol complex formed with an anionic polymer. The tramadol complex provides sustained release of tramadol for a synchronized (coordinated) release profile of acetaminophen and tramadol.04-29-2010
20090304793SUSTAINED RELEASE OPIOID FORMULATIONS AND METHODS OF USE - The invention combines two different subunits with different release profiles in novel sustained-release oral dosage forms. In particular, the oral dosage forms include a subunit that comprises an opioid analgesic and a sustained-release material, wherein the dissolution rate in-vitro of the subunit, when measured by the standard USP Drug Release test of U.S. Pharmacopeia XXVI (2003) <724>, is less than about 10% within about 6 hours and at least about 60% within about 24 hours; less than about 10% within about 8 hours and at least about 60% within about 24 hours; or less than about 10% within about 12 hours and at least about 60% within about 24 hours; the dosage form providing a duration of therapeutic effect of about 24 hours.12-10-2009
20090041844Modified Release Formulation - The invention is directed to the use of an extended release tablet formulation for pramipexole.02-12-2009
20130164377SHELL-AND-CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE - Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.06-27-2013
20110038931COMPOSITE PREPARATION - The present invention provides a combination preparation which comprises: a prior-release section comprising aspirin or a pharmaceutically acceptable salt thereof as a pharmacologically active component; and a delayed-release section comprising clopidogrel, an isomer thereof or a pharmaceutically acceptable salt thereof as a pharmacologically active component. The combination preparation of the present invention exhibits a far better effect in preventing platelet aggregation than does simultaneous oral therapy or treatment with the respective single preparations, and not only can it improve the patient's drug-taking compliance by administration once a day but it can also reduce the adverse reactions which follow long-term administration of aspirin. The combination preparation of the present invention is also advantageous in that it exhibits an outstanding effect in inhibiting blood platelet aggregation despite a reduction in the amount of aspirin ingested, and in that it converts clopidogrel resistance into susceptibility and prevents serious adverse reactions caused by clopidogrel resistance and in that it can be stored over the longer term since it is stable under common storage conditions.02-17-2011
20090047346Sustained release formulations of sotalol - Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.02-19-2009
20090011017POLYMERS BASED ON WATER-SOLUBLE MONOOLEFINIC COMPRISING COLLOIDAL SILICA AND THEIR USE AS MATRIX POLYMERS FOR SOLID DOSAGE FORMS - Copolymers obtained by free-radical polymerization of a mixture of 01-08-2009
20110212174CONTROLLED RELEASE ARGININE FORMULATIONS - A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. FIG. 09-01-2011
20100297229TAPENTADOL COMPOSITIONS - The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol Hydrochloride and therapeutically effective amount of a second analgesic, wherein the second analgesic is tramadol, gamma-aminobutyric acid (GABA) analogue or an NSAID. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a slow release Tapentadol Hydrochloride and a therapeutically effective amount of a second analgesic, wherein the second analgesic is tramadol, gamma-aminobutyric acid (GABA) analogue or an NSAID.11-25-2010
20110070304MANUFACTURE OF TABLET HAVING IMMEDIATE RELEASE REGION AND SUSTAINED RELEASE REGION - In one aspect, the present invention features a process for making a tablet including a pharmaceutically active agent wherein the tablet has both an immediate release region and a modified release region. The method includes the steps of: (a) forming a tablet shape including a powder blend containing a pharmaceutically active agent and a thermally-sensitive material; and (b) applying energy in different amounts to different regions of the tablet shape to form the tablet in a manner such that: (i) a first region of the tablet shape is exposed to said energy for a sufficient period of time to melt the thermally-sensitive material within the first region to form said modified release region of said tablet; and (ii) a second region of said tablet shape is not so exposed to the energy such that said second region forms the immediate release region of said tablet.03-24-2011
20080274180Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It - A pharmaceutical composition in the form of tablets constitutes an orally administered, controlled drug delivery system that will provide increased retention time of the device in the stomach over conventional dosage forms and release metformin or its pharmaceutically acceptable salt in a controllable manner, and further that is easy and inexpensive to manufacture.11-06-2008
20080292700CONTROLLED RELEASE FORMULATIONS USING INTELLIGENT POLYMERS - A controlled release pharmaceutical composition comprises (a) topiramate or a pharmaceutically acceptable salt thereof, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component. The polymer components are effective for controlled release of the pharmaceutically active substance from the composition.11-27-2008
20090155361TABLET WITH MULTIPLE DRUG-CONTAINING SECTIONS - A tablet which is either a two-layer tablet comprising a layer A and a layer B or a three-layer tablet comprising a layer A, a layer B and a layer C in that order, wherein the layer B is a medicinal additive layer, the layer A and the layer C are drug layers that are segmented on the layer B, and the sections of the layer A and the layer C are held on the layer B and contain either the same or different drugs. Also, a scored tablet wherein splitting at one of the score lines produces two fragments with equal drug contents and splitting at the other score line produces two fragments with unequal drug contents. In addition, a scored tablet wherein splitting at the score lines exposes cross-sections with different drug release-controlling functions.06-18-2009
20090028940PHARMACEUTICAL COMPOSITIONS OF RIFAXIMIN - A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.01-29-2009
20110300217HYDROMORPHONE THERAPY - A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.12-08-2011
20090202634PHARMACEUTICAL DOSAGE FORM - The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B08-13-2009
20110287101RAPID RELEASE MINI-TABLETS PROVIDE ANALGESIA IN LABORATORY ANIMALS - Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in mice for 3-9 days. Blood levels of analgesia peak at day-1 and are substantially complete by day-5 depending on the level of buprenorphine. These results demonstrate that post surgical implants provide clinically significant levels of analgesia in the 24-48 hour period following surgery and thus obviate the time consuming, expensive, and high-risk need to inject mice post surgery. The pellets are safe and easy to use. Placed in the surgical wound at the end of surgery, they provide 2-3 days of analgesia and obviate the need for subsequent handling of the animal for pain therapy. The implants have no detectable effect on mouse behavior, hematology, or liver chemistry. The unexpected release kinetics of the 5 mg pellet provides an ideal implant for post surgical analgesia. These implants solve a significant problem facing scientists who use rodents in research and abide by international of animal welfare.11-24-2011
20110287100Galenic Formulations of Organic Compounds - A solid unit dosage form of aliskiren for oral administration in the form of a tablet having a core and an outer coating is prepared such that the core contains a therapeutically effective amount of aliskiren and the outer coating is in the form of a film-coat with taste masking properties and/or can undergo controlled release.11-24-2011
20080299196Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.12-04-2008
20110293718Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same - Compositions of predetermined amounts of R(+) pramipexole and S(−) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.12-01-2011
20090017116EXTENDED RELEASE GLICLAZIDE FORMULATIONS - The present invention relates to an extended release (XL) pharmaceutical tablet composition for oral administration and methods of its manufacture. More particularly, the present invention relates to an extended release gliclazide formulation which does not increase the blood glucose level in human patients.01-15-2009
20110217374 PHARMACEUTICAL COMPOSITION SIMULTANEOUSLY HAVING RAPID-ACTING PROPERTY AND LONG-ACTING PROPERTY - Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least one release control base selected from the group consisting of water-insoluble polymer, and water-soluble viscous polymer, and a pharmaceutically acceptable carrier; and, an immediate release part comprising a second active pharmaceutical ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition exhibits independent release properties of the immediate release part and the sustained-release part by coating the surface of the sustained-release part comprising an active pharmaceutical ingredient, a release control base and a pharmaceutically acceptable carrier with a water-insoluble polymer to separate it from the immediate release part, and it may be prepared by a relatively simple process without specification limitation to the contents and the kinds of usable pharmaceutically active ingredients.09-08-2011
20090098202Extended Release Formulation - The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof.04-16-2009
20100112051TIANEPTINE SULFATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME - Disclosed herein is a novel sulfate salt of tianeptine with improved properties. Also described herein are novel pharmaceutical compositions comprising tianeptine sulfate salt, methods of making, and related methods of treatment.05-06-2010
20090148523SYSTEM AND PROCESS FOR PROVIDING AT LEAST ONE OPENING IN DOSAGE FORMS - The present invention relates to apparatus, methods, and processes for making solid dosage forms comprising at least one active ingredient, a core and shell configuration, wherein the shell comprises a hardenable material, such as a thermal-gelling polymer, for example gelatin; and the shell is provided with at least one opening. The opening(s) are formed while the shell is still in a softened state.06-11-2009
20120087979EXTENDED-RELEASE ORAL DOSAGE FORMS FOR POORLY SOLUBLE AMINE DRUGS - Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the intestine. Methods of making such dosage forms are also provided.04-12-2012
20090087487Paliperidone sustained release formulation - The present invention provides sustained release dosage forms comprising Paliperidone and processes for preparing the same.04-02-2009
20100189785Use of D-ribose for fatigued subjects - Low doses of D-ribose raise the level of fitness and lower the perception of fatigue in baby boomers aged 45-65 who perceive themselves as fatigued. The doses range from 0.100 grams to 3.0 grams, bid, for a total of 0.200 to 6.0 grams daily. Objective measures of cardiopulmonary parameters confirm the improvement of fitness and questionnaires confirm that quality of life and mental states are improved with D-ribose administration.07-29-2010
20090047345Sustained-release tramadol formulations with 24-hour efficacy - A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration 02-19-2009
20090202633Extended release formulations of guaifenesin - The present invention relates to extended release formulations comprising expectorant. More particularly, the present invention relates to extended release formulations comprising guaifenesin. The present invention also relates to a process for the preparation of extended release formulations comprising guaifenesin.08-13-2009
20080206331TABLET COMPRISING EFLETIRIZINE AND PSEUDOEPHEDRINE - The present invention concerns a tablet comprising two distinct segments. More particularly the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.08-28-2008
20080206333Extended Release Pharmaceutical Formulations of S-Adenosylmethionine - Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.08-28-2008
20080206332SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT - Sustained release oral dosage forms of R-baclofen and methods of treating diseases comprising orally administering such dosage forms are disclosed.08-28-2008
20110200671METHOD OF TREATING A DISEASE CONDITION SUSCEPTIBLE TO BACLOFEN THERAPY - The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.08-18-2011
20080274179Supercritical CO2 liquorice extract and products made there from - The present invention provides, in one aspect, to products made from a novel and non-obvious supercritical CO11-06-2008
20080279936Estradiol metabolites for reduction of endothelin production - Methods are provided for the decrease of endothelin production in an individual. In particular, the methods include the reduction of endothelin production by the administration of a composition comprising an estradiol metabolite. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol or prod rugs thereof. The composition may be in the form of a controlled release formulation. The present methods are useful as a therapeutic for a wide variety of disease states.11-13-2008
20080286358Wake up on time dietary supplement and method of use - A time-released dietary supplement is disclosed. The dietary supplement is meant be taken upon going to bed in the evening. The active ingredients are released during the night so the person will wake up energized and refreshed.11-20-2008
20080286357MULTI-FUNCTIONAL PARTICULATE DELIVERY SYSTEM FOR PHARMACOLOGICALLY ACTIVE INGREDIENTS - The present invention relates to a pharmacologic dosage unit which includes a multi-functional particulate system and a pharmacologically active agent. The multi-functional particulate system includes solid biologically-safe particles incorporated into a matrix and having a characteristic that each individual particle retains its original size. The invention also relates to methods of preparing, enhancing flow properties and compacting properties of a pharmacologic composition, increasing capacity for inclusion of ingredients, and increasing dispersion of actives. Finally, the invention includes a method for delivering an active agent to a patient.11-20-2008
20080268045SUSTAINED RELEASE METHOTREXATE FORMULATIONS AND METHODS OF USE THEREOF - Described herein are methods of treating a disease by treatment with oral sustained release methotrexate alone or in combination with folates. In some embodiments, these approaches improve the pharmacotherapeutic performance of methotrexate therapy.10-30-2008
20090162433METHOD OF TREATMENT - The invention provides the use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from overactive bladder.06-25-2009
20110142932Pharmaceutical Tablets Comprising a Plurality of Segments - Deeply scored pharmaceutical tablets are disclosed, along with pharmaceutical tablets with a score in a segment that adjoins a segment lacking a pharmacologically effective dose of any drug.06-16-2011
20090081291Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User - Aspects of the invention include a sustained release dosage form that can be administered to an oral cavity, e.g., the mouth. In certain embodiments, the sustained release dosage form is formulated as a lozenge or gum that may be administered to an oral cavity of a user for the purpose of dissolving over a prolonged period of time and thereby delivering an essential oil component therein. In certain embodiments, the sustained release dosage form includes a beneficial agent and, therefore, not only provides for the prolonged delivery of an essential oil component to an oral cavity, but also provides for the sustained release of a beneficial agent thereto. In certain embodiments, the sustained release dosage form includes a biocompatible, water-insoluble polymer, e.g., ethylcellulose and an essential oil component, which are combined in such a manner so as to produce a dosage form that substantially dissolves over a prolonged period of time when positioned within an aqueous environment, such as an oral cavity of a user. In certain embodiments, the sustained release dosage form may include an additional water soluble agent, such as gum arabic, which may be included so as to further provide the dosage form with a desired dissolution characteristic. In certain embodiments, the dosage form may also include a beneficial agent to be delivered to the mouth. Methods of formulating such dosage forms and administering them to an oral cavity for the treatment of an adverse condition are also provided herein.03-26-2009
20090202635Delivery System, Application, and Method - A sequenced biologically compatible delivery system, application, and method is provided, which increases therapeutic care of animals by conveniently and effectively supplying meticulous administration plans requiring sequential administration of varying biologically active agents.08-13-2009
20130189361COMBINATION TABLET WITH CHEWABLE OUTER LAYER - A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.07-25-2013
20090110727Extended release compositions of proton pump inhibitors - The invention provides extended release compositions comprising at least one proton pump inhibitor. The invention also provides methods for treating gastrointestinal disorders by administering the compositions of the invention to patients in need of gastrointestinal therapy.04-30-2009
20100255093SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG - Sustained release oral dosage forms of an R-baclofen prodrug are disclosed.10-07-2010
20100255094BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.10-07-2010
20090110728Zero-Order Modified Release Solid Dosage Forms - The invention comprises a solid dosage form for delivery of water soluble pharmaceutical agents. The solid dosage form comprises a matrix core containing the pharmaceutical agent and a hydrophobic material, and a coating containing a hydrophilic pore-forming agent and a hydrophobic polymer. The dosage form exhibits a zero-order release profile upon dissolution.04-30-2009
20100303907STANDARDIZED PLANT EXTRACT, PROCESS FOR OBTAINING THE SAME AND USES THEREOF - The present invention refers to a process for obtaining a standardized extract having antinociceptive, anti-inflammatory and antipyretic properties, from at least one part of a plant of genus 12-02-2010
20110123618Controlled release formulation of lamotrigine - Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations. It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day.05-26-2011
20090035372 METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE - The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product.02-05-2009
20110038930HOT-MELT EXTRUDED PHARMACEUTICAL DOSAGE FORM - The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side;02-17-2011
20090214644TRANEXAMIC ACID FORMULATIONS WITH REDUCED ADVERSE EFFECTS - Disclosed are delayed release oral tranexamic acid formulations and methods of treatment therewith.08-27-2009
20080248112USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES - Disclosed are methods for treating patients suffering from coronary microvascular disease comprising administering ranolazine to the patient. In one embodiment, ranolazine is administered as an oral dose10-09-2008
20110212173Controlled Release Treatment of Depression - There is described a pharmaceutical composition for controlled release of an active compound wherein the active compound is selected from the group comprising tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof for the treatment or alleviation of depression. More particularly, there is described an abuse resistant pharmaceutical composition for the treatment of inter alia, depression and controlled release pharmaceutical compositions of related thereto.09-01-2011
20110052685GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN - Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.03-03-2011
20100196473Pharmaceutical Composition Containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with Delayed Active Ingredient Release - Pharmaceutical compositions with delayed release which contains 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed active ingredient release, wherein the matrix contains 1 to 80 wt. % of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and exhibits the following in vitro release rate: 3-35 wt. % (relative to 100 wt. % of active ingredient) of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol released after 0.5 hours, 5-50 wt. % after 1 hour, 10-75 wt. % after 2 hours, 15-82 wt. % after 3 hours, 30-97 wt. % after 6 hours, more than 50 wt. % after 12 hours, more than 70 wt. % after 18 hours, and more than 80 wt. % after 24 hours.08-05-2010
20100068270BUPROPION HYDROBROMIDE POLYMORPHS - Polymorphous and amorphous forms of bupropion hydrobromide are described.03-18-2010
20100028427IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T02-04-2010
20100233260PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - The present invention relates to a pharmaceutical composition for oral administration comprising a modified release portion containing tamsulosin or a pharmaceutically acceptable salt thereof, and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof and a hydrophilic substance.09-16-2010
20090081290TAMPER RESISTANT DOSAGE FORMS - The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.03-26-2009
20100310653USE OF AN EXTRACT MADE OF LEAVES OF GINKGO BILOBA - The present invention relates to the use of an extract made of leaves of 12-09-2010
20100112052OSMOTIC TABLET WITH A COMPRESSED OUTER COATING - The present invention features a method of manufacturing an osmotic tablet including the steps of (i) compressing a tablet core including a first pharmaceutically active agent and a hydrophilic polymer; (ii) applying an osmotic coating to the outer surface of the tablet core to form a coated tablet, wherein the osmotic coating includes at least one opening exposing the tablet core; and (iii) compressing an immediate release coating onto the surface of the coated tablet, wherein the release coating includes a second pharmaceutically active agent.05-06-2010
20080292699SOLID PHARMACEUTICAL DOSAGE UNIT FOR ALLEVIATING SYMPTOMS OF RHINORRHEA - A solid pharmaceutical dosage unit for alleviating the symptoms of rhinorrhea. The dosage unit comprises an anticholinergic agent and an antihistamine and, optionally, a decongestant and, when placed in a basket in 500 ml of 0.01 N HCl of 37° C. which is stirred at 100 rpm, releases at least about 75% of the at least one anticholinergic agent within 45 minutes and releases the at least one antihistamine at a rate of from about 20% to about 60% after 2 hours, from about 45% to about 80% after 4 hours and at least about 75% after 8 hours. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.11-27-2008
20090191266Pregelatinized Starch In A Controlled Release Formulation - The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms prepared therefrom, preferably for once daily oral administration. The hydrophilic controlled release formulation comprises pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers and optionally pharmaceutically acceptable formulating agents. Preferred hydrophilic polymers include hydroxypropyl cellulose and hydroxypropyl methylcellulose.07-30-2009
20080311200Controlled Slow Release Formulation of Thiamine and Use Thereof in the Treatment of Pathologies Connected to Defective Process of Learning and Memorization - The present invention relates to thiamine controlled-release pharmaceutical compositions and their use in medicine for resolving absorption defects or deficiencies of thiamine itself from the organism. Said compositions have revealed to be useful in the treatment of cerebral pathologies connected with learning and memorizing processes. In particular, said compositions have revealed to be useful in the treatment of the Alzheimer's pathology, preferably in the forms of slight-medium intensity.12-18-2008
20110052686MODIFIED RELEASE LAMOTRIGINE TABLETS - The present invention relates to uncoated modified-release tablets of lamotrigine and the process for preparation thereof, wherein the tablets comprise a portion of lamotrigine in an admixture with a pH-dependent polymer.03-03-2011
20100015222GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC - Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.01-21-2010
20110091548USE OF A MATRIX FOR ORALLY ADMINISTERING SUSTAINED RELEASE MAGNESIUM, AND COMPOSITION CONTAINING SAID MATRIX - A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by weight of glyceryl behenate, 10 to 12 parts by weight of lactose and 10 to 12 parts by weight of colloidal silica. A non-enteric protective coating that slows down the gastric dissolution of the magnesium may comprise 15 to 75 parts by weight of shellac, cellulose ether or a mixture thereof. The tablet may be administered to patients in need thereof.04-21-2011
20120171287OSMOTIC PUMP CONTROLLED RELEASE TABLET AND PREPARATION METHOD THEREOF - An osmotic pump controlled release tablet and the preparation method thereof are disclosed. The osmotic pump controlled release tablet is composed of tablet core, semipermeable membrane and optional film coating. The material of said semipermeable membrane is composed of ethyl cellulose and povidone in the ratio of 1:1˜1:4 by weight. Said tablet core comprises drug containing layer and push layer. The osmotic pump controlled release tablet also characterizes in that; (1) the angle θ07-05-2012
20100092554COMBINATION WITH AN EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention is directed to a combination of an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof with a conventional treatment option of Parkinson's Disease.04-15-2010
20100247645PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN - The present invention relates to a pharmaceutical oral fixed dose combination comprising 09-30-2010
20100247646EXTENDED RELEASE TABLETS OF NISOLDIPINE - The present invention relates to extended release tablets comprising a core which comprises of nisoldipine, a rate-controlling hydrophilic polymer and optionally, an enteric agent. Such tablets may also be coated with a release rate-controlling coating comprising of a hydrophobic polymer or enteric agent or combinations thereof, in particular ethylcellulose, and Eudragits.09-30-2010
20120135077ABUSE RESISTANT OPIOID DRUG-ION EXCHANGE RESIN COMPLEXES HAVING HYBRID COATINGS - A sustained release formulation for opioid drugs is described. The formulation contains an opioid-ion exchange resin complex having a hybrid coating. The hybrid coating contains a cured polyvinylacetate polymer and a pH-dependent enteric coating layer mixed therein. Also provided are methods of making and using same.05-31-2012
20120219625CLARITHROMYCIN EXTENDED-RELEASE TABLET - The present application relates to an extended-release tablet for oral administration of Clarithromycin. The tablet comprises a water soluble diluent and an acidic compound wherein the acidic compound is used to increase the dissolution rate of Clarithromycin. The tablet is free from polymers or may comprise polymer that is insufficient to function as a release controlling agent.08-30-2012
20100172982SUSTAINED RELEASE FORMULATIONS OF DIVALPROEX SODIUM - A sustained release tablet formulation comprising an inner phase comprising a mixture of divalproex or its pharmaceutically acceptable salt and a hydrophobic agent, and an outer phase comprising a hydrophilic polymer, wherein the hydrophobic agent is present in amount ranging from 6.3% to about 8.3% by weight of the formulation.07-08-2010
20120219624PROCESS FOR PREPARING PRODUCTS COMPRISING STABILISED ACTIVES AND COMPOSITIONS COMPRISING SAME - The present invention broadly relates to a process for preparing products comprising active components, and in particular biological materials, wherein the active components are stabilised. The invention further relates to compositions comprising the products, and in particular compositions comprising therapeutic biological materials.08-30-2012
20100047345HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM FOR HYDROMORPHONE - Disclosed herein are oral dosage forms of hydromorphone that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described.02-25-2010
20090246277Controlled release system - The invention relates to a system for controlled release of medicinally active substances, which comprises sucrose acetate isobutyrate (SAIB) and a further solvent. 10-01-2009
20120258172Compositions For The Treatment of Central Nervous System Disorders Including Depression Employing Novel Drug Combination Therapy To Reduce Suicidality In Patients - Described herein are novel methods and formulations for reducing suicidality in human subjects. Such formulations and methods are a combination of lithium and one or more other CNS therapeutic agents such as anti-depressant, mood-stabilizing, anxiolytic, anticonvulsant, antipsychotic, anti-addictive, and appetite suppressant drugs.10-11-2012
20080299195USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE - This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose.12-04-2008
20110002989METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD - The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC01-06-2011
20100233259DOSAGE FORM OF ROPINIROLE - The present invention relates to a dosage form of Ropinirole. The dosage formulation of the invention is intended to control the release rate of one or more therapeutically active agents.09-16-2010
20110287099Sustained-release formulations of topiramate - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.11-24-2011
20100215744Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical - A method of producing a batch of a tetracycline-class component HPMC extended release pharmaceutical product having a desired dissolution profile, comprising: selecting a dissolution rate-controlling polymer comprising an HPMC component, the HPMC component having a selected % HP value; validating that the % HP in the selected HPMC component is such that a mean sample of the product complies with the desired dissolution profile over each time point in the dissolution profile, and preparing the product by preparing a formulation comprising a pharmaceutically effective amount of the tetracycline-class chemical and the selected HPMC component with the % HP value. There is also provided a method of predicting the dissolution rate profile over a number of dosage forms.08-26-2010
20100215743Composition and drug delivery of bisphosphonates - The present invention provides methods of treating or preventing a medical condition that is responsive to a bisphosphonate compound in a subject. The methods comprise administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the bisphosphonate no less frequently than a bi-weekly dosage schedule. In some embodiment, the bisphosphonate compound is zoledronic acid.08-26-2010
20120100212TABLET HAVING HOLLOW STRUCTURE - A water floatable tablet, which is either: 04-26-2012
20130011478PHARMACOLOGICALLY OPTIMIZED MULTIMODAL DRUG DELIVERY SYSTEM FOR NORDIHYDROGUIARETIC ACID (NDGA) - The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.01-10-2013
20080241240COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS - The present invention relates to a chronotherapeutic combination pharmaceutical formulation, which is designed to control the release of each ingredient of the combined drug in a predetermined rate based on the principle of the so-called chronotherapy and xenobiotics, where drugs are administered to exhibit pharmacological activities at predetermined time intervals. The formulations of the present invention comprise a dihydropyridine, and a statin, as active ingredients. The formulations are structured and arranged such that the respective release rates of the above ingredients can be controlled, thereby reducing or preventing antagonistic effects and side effects resulting from the interaction of the above ingredients, while maintaining the synergistic effect, and providing easy medication.10-02-2008
20080233191USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE - This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose.09-25-2008
20080226716AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATION OF GABA ANALOGUES - Compounds that provide for sustained systemic concentrations of GABA analogs following oral administration to animals are disclosed. Pharmaceutical compositions including, and methods using, such compounds are also disclosed.09-18-2008
20080226715THERAPEUTIC COMPOSITIONS AND METHODS - The present invention provides compositions, methods and kits for treating, preventing or reducing the risk of developing a CNS disorder. In general, the invention involves utilizing caffeine for preventing or alleviating pathological symptoms of a CNS disorder, such as headache, epilepsy, pain, Parkinson's disease, psychiatric disorders such as anxiety, bipolar disorder, depression, and schizophrenia, ADD, and ADHD.09-18-2008
20080226714SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION - The present invention relates to sustained-release tablet formulations of piperazine-piperidine compounds, which can be useful in treating central nervous system disorders; to processes for their preparation; and to methods of using them.09-18-2008
20080226713Controlled Release Pharmaceutical Compositions of Tolperisone for Oral Administration - The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a tablet or granule, a specific release of active substance can be adjusted which is matched to the special genotype in the metabolisation of tolperisone. At the same time, as a result of the very uniform and persistent release of tolperisone, the in vivo inversion of enantiomerically pure tolperisone that is known from the art can be adjusted in favour of the R(−)tolperisone which is prominent in muscle-relaxing therapy.09-18-2008
20080213363Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa - Compositions, methods, and formulations for delivering 5-HT09-04-2008
20100316709ORALLY DISINTEGRATING SOLID PREPARATION - The present invention provides an orally-disintegrating solid preparation comprising fine granules showing controlled release of a pharmaceutically active ingredient, wherein the outermost layer of the fine granules is coated with a coating layer comprising hydroxypropylmethylcellulose and low-substituted hydroxypropylcellulose and breakage of the fine granules during tableting is suppressed.12-16-2010
20110274754ORAL TABLET COMPOSITIONS OF DEXLANSOPRAZOLE - Oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof having a gradual release and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.11-10-2011
20120282337Modified Release Formulation - The invention is directed to the use of an extended release tablet formulation for pramipexole.11-08-2012
20110311626CONTROLLED RELEASE COMPOSITIONS COMPRISING ANTI-CHOLINERGIC DRUGS - The present invention provides compositions comprising dicyclomine, or salts, and/or solvates and methods of making and using the compositions to treat intestinal hypermotility or Irritable Bowel Syndrome (IBS). The present invention also provides once-a-day orally disintegrating dosage forms comprising compositions of the present invention.12-22-2011

Patent applications in class Sustained or differential release type

Patent applications in all subclasses Sustained or differential release type